8月26日新天药业主力资金净流出6676.97万元，占流通市值的2.18%。近五个交易日主力资金累计净流 出1.37亿元，占流通市值的4.47%。 风险提示：股市有风险，投资需谨慎。 新天药业股价报12.81元，较前一交易日下跌0.50元，跌幅3.76%。盘中最高触及13.47元，最低下探至 12.78元，成交量为39.15万手，成交金额达5.08亿元。 新天药业属于中药行业，公司专注于中成药、化学药的研发、生产和销售。8月26日公司接待了包括摩 根士丹利基金、财通基金等多家机构的调研，就公司在研管线进展等问题进行了交流。调研信息显示， 公司在肿瘤辅助治疗药物改良型新药研发方面取得进展。 ...

公司近期在互动平台回应投资者称，目前与维眸生物在眼科药物方面暂无协同效应，且不掌握对方在研 创新药的相关信息。根据公司披露的半年报显示，2025年上半年归属于上市公司股东的净利润为2.90亿 元，较上年同期下降13.87%。 风险提示：以上内容仅供参考，不构成任何投资建议。市场有风险，投资需谨慎。 截至2025年8月26日收盘，仁和药业股价报6.44元，较前一交易日下跌0.17元，跌幅2.57%。当日成交量 为102.45万手，成交金额达6.62亿元。 仁和药业主要从事中成药、化学药、原料药及健康相关产品的研发、生产和销售。公司产品涵盖感冒 药、妇科用药、消化系统用药等多个治疗领域。2025年上半年，公司实现营业收入19.75亿元，同比下 降16.46%。 ...

新天药业主要从事中成药、化学药的研发、生产和销售，产品涵盖感冒药、心脑血管用药等多个领域。 公司所属行业为医药制造业，涉及中药、流感等概念板块。 风险提示：股市有风险，投资需谨慎。 截至2025年8月22日收盘，新天药业股价报12.55元，较前一交易日下跌2.18%。当日股价波动明显，开 盘报13.00元，最高触及13.29元，最低下探12.49元，振幅达6.24%。盘中曾出现快速反弹，10点04分时5 分钟内涨幅超过2%，成交金额达1.82亿元。 从资金流向来看，8月22日主力资金净流出513.17万元，近五日累计净流出324.83万元。当日换手率为 14.66%，成交量为34.99万手，成交金额达4.48亿元。 ...

Group 1 - The stock price of Taiji Group is reported at 23.21 yuan, down 0.25 yuan or 1.07% from the previous trading day, with a trading volume of 136,551 hands and a transaction amount of 319 million yuan [1] - Taiji Group is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drugs, and biopharmaceuticals, covering various therapeutic areas including digestive, respiratory, cardiovascular, and anti-infection [1] - The company disclosed its semi-annual report for 2025, showing a revenue of 5.658 billion yuan, a year-on-year decrease of 27.63%, and a net profit attributable to shareholders of 139 million yuan, down 71.94% year-on-year, mainly due to policy impacts and inventory digestion of certain products [1] Group 2 - The company announced plans to publicly transfer a vacant property in Chengdu with an assessed value of 39.136 million yuan [1] - In terms of capital flow, Taiji Group experienced a net outflow of 30.6396 million yuan on the day, with a cumulative net outflow of 237.7444 million yuan over the past five days [1]

本文源自：金融界 中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生 产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗 领域具有优势。公司自从2000年上市以来，在MSCI全球标准指数、恒生指数等多个指数中成为成分 股，连续六年入选《制药经理人》的"全球制药企业TOP50"，核心企业正大天晴药业集团、北京泰德制 药股份有限公司多年位列中国医药工业企业百强榜，公司产品收入占比逐年提升。 作者：行情君 截至2025年中报，中国生物制药营业总收入175.75亿元、净利润33.89亿元。 8月21日，中国生物制药(01177)盘中上涨2.01%，截至09:58，报7.61元/股，成交3.03亿元。 8月19日，浦银国际证券维持买入评级,目标价9.1港元。 ...

Company Overview - Zhongsheng Pharmaceutical closed at 22.79 yuan on August 20, down 1.04 yuan, a decrease of 4.36% from the previous trading day [1] - The opening price was 23.39 yuan, with a high of 24.34 yuan and a low of 22.50 yuan, and the trading volume reached 661,194 hands with a transaction amount of 1.537 billion yuan [1] Business Operations - Zhongsheng Pharmaceutical is primarily engaged in the manufacturing of pharmaceuticals, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and biological drugs [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-infection, digestive system, and respiratory system [1] Market Activity - On the morning of August 20, Zhongsheng Pharmaceutical experienced a rapid rebound, with a rise of over 2% within 5 minutes, peaking at 24.01 yuan [1] - The net outflow of main funds on that day was 120.6993 million yuan, while the net inflow over the past five days was 14.899 million yuan [1]

益佰制药发布公告称，拟以8000万元受让控股子公司益佰中药配方颗粒制药有限公司40.03%的股权， 交易完成后将持有该公司100%股权。公司2025年半年报显示，上半年实现营业收入9.93亿元，同比下 降15.0%；归母净利润亏损1990万元，较去年同期亏损1.06亿元有所收窄。 益佰制药股价报4.55元，较前一交易日下跌0.87%。开盘价为4.66元，盘中最高触及4.75元，最低下探 4.47元，成交量为1121773手，成交金额达5.18亿元。 风险提示：股市有风险，投资需谨慎。 该公司主营业务为医药工业、医疗服务和大健康产业。医药工业板块主要产品包括化学药、中成药和生 物药，涉及肿瘤、心脑血管、妇科等多个治疗领域。医疗服务板块运营综合性医院和肿瘤专科医院，大 健康产业板块则开发以苗药为特色的健康产品。 来源：金融界 ...

Group 1 - The stock price of Weikang Pharmaceutical as of August 18, 2025, is 25.24 yuan, down 0.86% from the previous trading day [1] - The stock exhibited volatility, opening at 25.25 yuan, reaching a high of 26.00 yuan, and a low of 24.59 yuan, with an amplitude of 5.54% [1] - There was a rapid rebound in the stock price, with a more than 2% increase within 5 minutes at 9:35 AM, and a transaction amount of 25.85 million yuan [1] Group 2 - Weikang Pharmaceutical focuses on pharmaceutical manufacturing, with main business activities including the research, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company's products cover multiple therapeutic areas, including medications for respiratory and digestive system diseases [1] Group 3 - The net outflow of main funds for Weikang Pharmaceutical on that day was 18.22 million yuan, with a cumulative net outflow of 21.31 million yuan over the past five days [1] - The turnover rate for the day was 6.92%, with a trading volume of 99,688 hands and a total transaction amount of 252 million yuan [1]

Group 1 - The latest stock price of Zhongsheng Pharmaceutical is 22.96 yuan, up 1.91% from the previous trading day, with an intraday high of 23.54 yuan and a low of 22.38 yuan, and a total trading volume of 1.633 billion yuan [1] - The company’s main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, raw materials, and health products, covering multiple therapeutic areas such as cardiovascular, respiratory, and digestive systems [1] - Zhongsheng Pharmaceutical's third extraordinary general meeting of shareholders in 2025 approved the proposal regarding the redemption of part of the equity of its controlling subsidiary and related transactions, indicating an adjustment in the company's equity structure [1] Group 2 - Data on capital flow shows a net inflow of 41.5428 million yuan from main funds on that day, accounting for 0.24% of the circulating market value, while the cumulative net outflow over the past five trading days reached 96.9596 million yuan, representing 0.55% of the circulating market value [1]

对于利润相较去年同期有所下降的情况，白云山表示，受需求不足、行业竞争加剧及行业政 策等因素的持续影响，公司部分业务经营业绩有所下降。 旗下板块业绩分化 研发费用大幅缩减 记者注意到，白云山的经营性现金流持续为负值，由去年同期的 -20.37 亿元进一步减少至 -33.97 亿元，同比减少 66.79% 。公告显示，主要系公司下属企业货款回收有所下降，同 时采购支付金额增加所致。为缓解现金流压力，白云山加大了筹资力度，筹资活动现金流净 额达 19.18 亿元，同比提高了 222.36% ，主要是银行借款增加。 【导读】白云山发布 2025 年中期业绩报告，归母净利润同比下降 1.31% 见习记者 荧墨 8 月 15 日晚间，白云山（ 600332.SH ； 00874.HK ）发布 2025 年中期业绩报告。在医 药行业整体承压的背景下，白云山实现营业收入 418.35 亿元，同比增长 1.93% ；归母净利 润为 25.16 亿元，同比下降 1.31% ；扣非净利润为 22.06 亿元，同比下降 5.78% 。 2025 年上半年，白云山主要产品中成药、化学药、大南药合计的营收全线 " 瘦身 " ：中成 药收 ...